DVC Deutsche Venture Capital, one of the leading European venture capital companies based in Munich, invests in the fourth quarter of 2003 approx. 6.8 million Euro as lead investor in the innovative high tech companies Apertio Limited and KLOTZ DIGITAL AG and as co-investor in GLYCART Biotechnology AG. In January 2004, Thomas P. Limberger, CEO GE Germany, Austria, Switzerland joins the advisory board of DVC and Dr. Jan zur Hausen is appointed Partner of the life sciences team.
